{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
testosterone undecanoate
to a specific field?
Status:
US Previously Marketed
Source:
FLUOXYMESTERONE by WATSON LABS
(1983)
Source URL:
First approved in 1956
Source:
HALOTESTIN by PHARMACIA AND UPJOHN
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is a synthetic, orally active androgenic-anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone developed by Pharmacia & Upjohn Company LLC, approved by FDA at 1956. Fluoxymesterone is used in the treatment of hypogonadism in males and breast cancer in women. Fluoxymesterone has a relatively high ratio of androgenic to anabolic activity similarly to testosterone. Like many 17α-alkylated AAS, it has a relatively low affinity for the androgen receptor (AR). However, its actions are mediated by the AR, most likely due to its relatively long elimination half-life of approximately 9.2 hours.
Status:
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
STANOLONE, also known as dihydrotestosterone, is a potent androgenic metabolite of testosterone and anabolic agent for systemic use. It may be used as a replacement of male sex steroids in men who have androgen deficiency, for example as a result of the loss of both testes, and also the treatment of certain rare forms of aplastic anemia which are or may be responsive to anabolic androgens.
Status:
Possibly Marketed Outside US
First approved in 2011
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Resveratrol, a natural non-flavonoid polyphenol, exhibits a wide range of beneficial properties as an anticancer agent, a platelet anti-aggregation agent, and an antioxidant, as well as its anti-aging, anti-inflammatory, antiallergenic. This compound is in phase III clinical trials in combination with carboxymethyl-β-glucan for improving nasal symptoms in children with pollen-induced allergic rhinitis. Also in phase III clinical trial in the treatment of painful knee osteoarthritis and in type 2 diabetic patients. It has been demonstrated that resveratrol may prevent type 2 diabetic by targeting Sirtuin type 1 (SIRT1), indicating that SIRT1 may be a novel therapeutic target for diabetes prevention.
Status:
Possibly Marketed Outside US
Source:
Artec by Ecolab Inc.
(2000)
Source URL:
First approved in 2000
Source:
Artec by Ecolab Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
ANDA040069
(1996)
Source URL:
First approved in 1996
Source:
ANDA040069
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Creatinine is a product of metabolism of creatine phosphate, a molecule that serves as a rapidly mobilizable reserve of a brain and skeletal muscle. Creatinine is excreted by kidneys with little or no reabsorption. Serum creatinine is the most commonly used indicator of renal function.
Status:
Possibly Marketed Outside US
Source:
Unknown by Clark, L.C.|Kochakian, C.D.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Epitestosterone (17alpha-hydroxy-4-androsten-3-one) is a naturally occurring epimer of testosterone. It apparently parallels the formation of testosterone, but on the other hand its concentration is not influenced by exogenous administration of testosterone. This fact creates the basis of the present doping control of testosterone abuse. Epitestosterone can be considered as a weak antiandrogen in the term of displacement of androgen from receptor binding and as an efficient inhibitor of 5 alpha-reductase. Epitestosterone exerts androgen receptor-independent neuroprotective activity in vitro.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Testosterone valerate, or testosterone pentanoate, is a synthetic, steroidal androgen. It is a short-to-medium duration C17β valerate ester of testosterone, with a terminal half-life of approximately twice that of the short-acting testosterone propionate. Testosterone valerate is available exclusively as a component of the veterinary drug Deposterona developed by Syntex Animal Health Company, which is marketed in Mexico. Deposterona also contains testosterone acetate and testosterone undecanoate and is used to treat impotence, weakness, fatigue and hypogonadism in male breeding animals (cows, pigs, canines, sheep), as well as a general protein-sparing anabolic. It is administered via intramuscular injection and acts as a long-lasting prodrug of testosterone. Esterified forms of testosterone are designed to prolong the window of therapeutic effect following administration, allowing for less frequent injection schedule compared to injections of unesterified steroid. Deposterona is also used for bodybuilding purposes in men and not recommended for women performance-enhancing purposes due to its strong androgenic nature, side effects, and slow-acting characteristics (making blood levels difficult to control). Deposterona is only known to be manufactured in Mexico. Because it contains a low concentration of steroid,this product is not in high demand, and not readily diverted for illicit sale.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Testosterone acetate, a testosterone ester, is an androgen. It is a steroid lipid molecule considered to be practically insoluble (in water) and basic. It is an anabolic steroid and testosterone prodrug. Testosterone acetate has a faster rate of absorption in the body then other esters. In combination with two other testosterone esters, testosterone valerate and testosterone undecanoate, it is a part of Deposterona, an injectable veterinary blend steroid preparation marketed in Mexico. With its blend of slow and fast-acting esters, Deposterona is essentially a low dosed alternative to Sustanon and is used primarily to treat impotence, weakness, fatigue, and hypogonadism in male breeding animals (cows, pigs, canines, and sheep), and also as a general protein-sparing anabolic. Testosterone acetate is classified as a Schedule III drug by the United States Drug Enforcement Agency and is only legal with a prescription due to his potential for misuse and abuse.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Boldenone (INN, BAN), also known as Δ1-testosterone, 1-dihydrotestosterone, or androsta-1,4-dien-3-one-17β-ol (train name Equipoise) is a long-acting injectable anabolic agent for horses, supplied in a vial providing 50 mg boldenone undecylenate per mL in sesame oil with 3% (w/v) benzyl alcohol as a preservative. The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis increases appetite and stimulates the release of erythropoietin in the kidneys. Boldenone was synthesized in an attempt to create a long-acting injectable methandrostenolone (Dianabol), for androgen deficiency disorders. Boldenone acts similar to methandrostenolone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and all the associated progestogenic side effects. Equipoise (Boldenone Undecylenate Injection) is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and overexertion. Boldenone improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized. Boldenone should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases, and traumatic injuries.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Iophendylate (Pantopaque (in USA) or Myodil, formerly manufactures by Glaxo Laboratories (London,UK) was commonly used from the 1940s until the late 1980s for myelography, cisternography, and ventriculography; the use of oil-based contrast agents such as Myodil has been discontinued, and images of intradural oil-based contrast are rarely encountered at present. In 1942 Van Wagenen (a neurosurgical colleague of Warrens, at the University of Rochester) identified Iophendylate as causing chemical meningitis in 30 patients where "space-displacing masses within the spinal canal were suspected". Iophendylate has been shown to be both a radiographic and magnetic resonance (MR) contrast agent in patients with suspected cord abnormalities who underwent MR examination following myelography. The iophendylate appears as a linear band of high signal intensity along the dependent portion of the spinal canal on MR images obtained with a repetition time of 500 msec and an echo time of 30 msec. Recently was published report, where depicted a unique case of posteriorly located subdural trapped Myodil, about three decades after myelography. The clinical picture of that case highlighted that such a complication didn’t carry the risk of arachnoiditis and could remain silent for several decades. Although Iophendylate is not used for evaluation of spinal disease anymore in the modern diagnostic era, its former use and its intrathecal persistence makes its recognition in MR imaging important. That case emphasized the necessity of awareness about these rare features which continue to present even decades after abandonment of oil-based myelography.
